As of Jan 20
| -0.04 / -1.69%|
The 3 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +72.41% increase from the last price of 2.32.
The current consensus among 3 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.